Preoperative Atorvastatin Treatment in CABG Patients Rapidly Improves Vein Graft Redox State by Inhibition of Rac1 and NADPH-Oxidase Activity

Background— Statins improve clinical outcome of patients with atherosclerosis, but their perioperative role in patients undergoing coronary artery bypass grafting (CABG) is unclear. We hypothesized that short-term treatment with atorvastatin before CABG would improve the redox state in saphenous vein grafts (SVGs), independently of low-density lipoprotein cholesterol (LDL)-lowering. Methods and Results— In a randomized, double-blind controlled trial, 42 statin-naïve patients undergoing elective CABG received atorvastatin 40 mg/d or placebo for 3 days before surgery. Circulating inflammatory markers and malondialdehyde (MDA) were measured before and after treatment. SVG segments were used to determine vascular superoxide (O2·−) and Rac1 activation. For ex vivo studies, SVG segments from 24 patients were incubated for 6 hours with atorvastatin 0, 5, or 50 &mgr;mol/L. Oral atorvastatin reduced vascular basal and NADPH-stimulated O2·− in SVGs (P<0.05 for all versus placebo) and reduced plasma MDA (P<0.05), independently of LDL-lowering and of changes in inflammatory markers. In SVGs exposed to atorvastatin ex vivo, without exposure to LDL, basal and NADPH-stimulated O2·− were significantly reduced (P<0.01 for both concentrations versus 0 &mgr;mol/L) in association with a striking reduction in Rac1 activation and 1 membrane-bound Rac1 and p67phox subunit. The antioxidant effects of atorvastatin were reversed by mevalonate, implying a dependence on vascular HMG-CoA reductase inhibition. Conclusions— Short-term treatment with atorvastatin 40 mg/d before CABG improves redox state in SVGs, by inhibiting vascular Rac1-mediated activation of NADPH-oxidase. These novel findings suggest that statin therapy should be maintained or initiated in patients undergoing CABG, independently of LDL levels. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01013103.

[1]  D. Waters,et al.  Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. , 2009, Journal of the American College of Cardiology.

[2]  K. Griendling,et al.  NADPH oxidases: molecular understanding finally reaching the clinical level? , 2009, Antioxidants & redox signaling.

[3]  K. Channon,et al.  MTHFR 677 C>T Polymorphism Reveals Functional Importance for 5-Methyltetrahydrofolate, Not Homocysteine, in Regulation of Vascular Redox State and Endothelial Function in Human Atherosclerosis , 2009, Circulation.

[4]  Børge G Nordestgaard,et al.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[5]  M. Brookhart,et al.  Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery , 2008, Circulation.

[6]  J. Fleg,et al.  Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial. , 2008, The American journal of cardiology.

[7]  K. Komori,et al.  Pitavastatin inhibits intimal hyperplasia in rabbit vein graft. , 2008, The Journal of surgical research.

[8]  C. Ballantyne,et al.  Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. , 2008, American heart journal.

[9]  F. Violi,et al.  Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. , 2007, European heart journal.

[10]  M. Crabtree,et al.  Altered Plasma Versus Vascular Biopterins in Human Atherosclerosis Reveal Relationships Between Endothelial Nitric Oxide Synthase Coupling, Endothelial Function, and Inflammation , 2007, Circulation.

[11]  S. Neubauer,et al.  5-Methyltetrahydrofolate Rapidly Improves Endothelial Function and Decreases Superoxide Production in Human Vessels: Effects on Vascular Tetrahydrobiopterin Availability and Endothelial Nitric Oxide Synthase Coupling , 2006, Circulation.

[12]  G. Schuler,et al.  Endothelial Protection, AT1 Blockade and Cholesterol-Dependent Oxidative Stress: The EPAS Trial , 2006, Circulation.

[13]  J. Fontaine,et al.  Rosuvastatin treatment protects against nitrate‐induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway , 2006, British journal of pharmacology.

[14]  D. Harrison,et al.  Vascular NADPH oxidases as drug targets for novel antioxidant strategies. , 2006, Drug discovery today.

[15]  Elina Taneva,et al.  Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. , 2006, The American journal of cardiology.

[16]  W. März,et al.  Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans , 2005, Circulation.

[17]  W. Vaughn,et al.  Statins Are Associated With a Reduced Incidence of Perioperative Mortality After Coronary Artery Bypass Graft Surgery , 2004, Circulation.

[18]  K. Yusoff,et al.  Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. , 2003, Atherosclerosis.

[19]  F. Miller,et al.  Profiling the progression of cancer: Separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis , 2003, Proteomics.

[20]  Y. Hattori,et al.  HMG-CoA Reductase Inhibitor Increases GTP Cyclohydrolase I mRNA and Tetrahydrobiopterin in Vascular Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[21]  J. Holtz,et al.  Induction of NAD(P)H Oxidase by Oxidized Low-Density Lipoprotein in Human Endothelial Cells: Antioxidative Potential of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Therapy , 2001, Circulation.

[22]  C. Dessy,et al.  Hydroxy-Methylglutaryl–Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance , 2001, Circulation.

[23]  K. Channon,et al.  Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. , 2000, Circulation research.

[24]  D. Harrison,et al.  Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. , 1999, Biochemical and biophysical research communications.

[25]  W. Wąsowicz,et al.  Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. , 1993, Clinical chemistry.

[26]  T. Matsubara,et al.  Increased superoxide anion release from human endothelial cells in response to cytokines. , 1986, Journal of immunology.